Sai Life Sciences Ltd (SAILIFE) Q1 FY27 Earnings Call: Guides 15-20% Revenue Growth, Adds 3 Commercial Contracts

Sai Life Sciences Ltd held its Q1 FY27 earnings call on August 06, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline numbers and segment performance

• Rs.553 crore total revenue in Q1 FY 2026-2027 — 12% YoY growth from Rs.496 crore in Q1 FY 2025-2026.
• CRO revenue grew 26% YoY — contributed 40% of total revenue; CDMO grew 6% YoY, contributing 60%.
• Returning customers drove over 90% of revenue in both FY 2025-2026 and FY 2026-2027, reflecting strong retention and wallet-share expansion.
• EBITDA margin guidance of 28-30% reaffirmed by management as a long-term target.
• EcoVadis Platinum rating secured for 2026 — the company cited securing the "EcoVadis Platinum rating for 2026" placing it among the top 1% of assessed companies worldwide for sustainability.

Client breadth, molecule progression, and commercial wins

• 19 of the top 25 large pharma companies are active customers — a base that supports project retention and pipeline growth across discovery, development, and commercial stages.
• 33 active commercial molecules in the CMC business, with 14 molecules in late-stage development and 6 late-stage molecules added over the last 15 months; five of the six came from large pharma clients with ongoing FTE engagements.
• 4 commercial contracts (CRs) expected in FY 2026-2027 — 3 were added in Q1 FY27 and are described as "decently sized" by management; for 2 of these 3 the company expects to be the primary supplier (noted as anecdotal).
• 150-160+ earlier-stage projects are tracked, though management noted high failure rates; 4 late-stage Phase 3 molecules have been identified from public sources (revenue not disclosed due to material non-public information).
• 4-5% of Q1 FY 2026-2027 revenue came from new modalities (CRO/CDMO), limited to discovery and development sides — not commercial yet.
• One customer received FDA approval in FY 2025-2026; two more have regulatory milestones in FY 2026-2027, and one is expected in Q2 FY 2027-2028.

Expansion plans, capital allocation, and peptide build-out

• FY 2026-2027 CAPEX guidance maintained at Rs.1,100-1,300 crores — no FY 2027-2028 CAPEX guidance has been issued yet; management said it will be communicated at an appropriate time.
• Total capacity to reach 1,15,000 kiloliters by FY 2026-2027, confirmed on track by management, supporting the expected H2 ramp.
• Vizag expansion of 450 KL across two production blocks is on schedule — the first block is expected to be ready for operation in H2 / Q3 FY 2026-2027.
• Peptide program total capex expected to be less than Rs.300 crores from inception through FY 2027-2028; a GMP pilot-scale facility for clinical supplies is coming online in the near term, with true commercial capacity being built out for FY 2027-2028.
• Discovery capacity built in Q1 FY27 is already sold out — ahead of the typical 1-1.5 year timeline to fill, underscoring demand strength.
• Formulation capacity for clinical supplies up to Phase II is targeted to be operational within ~6 months (Q4 FY 2026-2027), driven by customer "China plus one" supply strategy demand.

Multi-modality transition, AI, and competitive positioning

• Multi-modality CRDMO strategy is underway — peptides are a key modality with a first dedicated lab coming online shortly for a top-tier pharma; an XCC Center of Excellence (payloads, linkers, conjugation) is close to opening.
• AI initiatives focus on eliminating non-value-add activities for chemists and operators; the high-throughput experimentation (HTE) platform is a separate, distinct effort.
• Boston facility (est. end of 2020) contributed to a 30-35% CAGR in discovery revenue over the last 4-5 years (period ending Q1 FY 2026-2027) by cultivating customer relationships early; the Manchester facility brings large-pharma-experienced talent working in tandem with India and US teams.
• Integrated service delivery (discovery chemistry, biology, DNPK) is used by ~65% of customers (primarily biotech); management hopes to transition at least two large pharma customers to this model in FY 2026-2027.
• Scientific excellence highlighted — a joint paper with AstraZeneca on batch/kinetic determination and a successful scale-up of a late-stage GMP intermediate using flow chemistry.
• Management declined to discuss the rationale for not entering monoclonal antibodies or protein-based therapeutics, deferring the strategy announcement to a later date; no fermentation capacity is included in the current capex plan.

Revenue trajectory, management stance, and macro tailwinds

• Medium-term revenue growth guidance of 15-20% (3–5 years from FY 2026-2027) reaffirmed — management described a "medium-term (3–5 year, from FY2026-2027) growth guidance of 15-20%" as a directional target that accounts for industry lumpiness; the company grew ~30% in FY 2025-2026, exceeding this range.
• H2 FY 2026-2027 expected to be stronger than H1, reverting to the historical 40-60 H1/H2 split (vs the 48-52 split seen in FY 2025-2026), supported by capacity additions coming online by end of Q2 / early Q3 FY27.
• Management reiterated a bullish outlook — "the trajectory is validated quarter-on-quarter through customer interactions" — with continued focus on building science capabilities before capacity to deliver long-term value.
• Large pharma relationships accelerating in scale and scope, with customers seeking sustainable 5-10 year partnerships; the FTE model started ~15 months ago has progressed to one customer working end-to-end, with 6 molecules now in Phase 3 development through this process.
• Geopolitical uncertainty strengthening India's role in pharma diversification — management cited 18 biotech IPOs in the US as a signal of future capital flow into new, leaner biotechs, which could expand the addressable pipeline.